Last close As at 05/08/2026
GBP0.05
— 0.00 (0.00%)
Market capitalisation
GBP20m
Research: Metals & Mining
CleanTech Lithium (CTL) is positioned for a transformational step-change following the agreement of a 40-year special lithium operating contract (CEOL) and the completion of a robust pre-feasibility study (PFS) for its flagship Laguna Verde project. These milestones significantly de-risk the project’s regulatory pathway and demonstrate compelling economics for a low-cost operation targeting 15,000tpa of battery-grade lithium carbonate. With a clear path to production and a strategic partner selection process underway, CTL is well positioned to become a sustainable lithium producer in the Atacama region.
The independent PFS, released on 31 March 2026, confirms the project’s strong technical
potential and favourable economics over a 25-year mine life. Based on a long-term
lithium carbonate price of
In a significant de-risking event, on 10 March CTL announced that it had agreed to
the contractual terms of a 40-year CEOL with the Chilean government. The contract
covers 153km2 and encompasses all project phases, including exploration, construction, production
and closure. State participation is limited to royalties (c 6% at
The CTL share price showed encouraging signs of recovery at the beginning of the year on the back of the rebound in lithium prices. However, despite the positive newsflow this price action was short-lived, and the shares are currently down c 40% from their recent peak. With a market cap of just £15m, CTL appears to be on the right track to further advance the Laguna Verde project towards production, with key upcoming catalysts including the ASX dual-listing, environmental permitting, strategic partner selection and the BFS.
|
Historical financial summary |
||||
|---|---|---|---|---|
| Year end | Revenue (£m) | PBT (£m) | EPS (£) | P/E (x) |
| 12/23 | 0.0 | 5.9 | (0.11) | N/A |
| 12/24 | 0.0 | 7.2 | (0.08) | N/A |
The PFS defines a dual-site configuration designed to leverage existing regional industrial capacity while minimising the environmental impact at high altitude. The Laguna Verde Site hosts the wellfield and a lithium chloride (LiCl) production facility utilising DLE and concentration technologies to produce a transportable solution containing approximately 5.9% lithium. This concentrated eluate will be transported by truck to the Copiapó site, where a downstream plant will handle conversion to 15,000tpa of battery-grade lithium carbonate. Locating the carbonation facility in a regional mining hub provides access to superior logistics and a skilled labour pool, with 70% of the operational workforce based at this site.
CTL will utilise a commercially proven alumina-based adsorbent DLE technology from Lanshen (Li-201), which achieved a 90% lithium recovery rate in semi-industrial pilot trials. Compared to traditional solar evaporation, the DLE-plus-reinjection model enables faster production cycles and higher global lithium recoveries of 85.5%. The process flowsheet is engineered for high efficiency, targeting a 98.4% internal water recovery through a sequential membrane train including nanofiltration, reverse osmosis and electrodialysis, followed by mechanical vapour recompression. The process eliminates the need for large evaporation ponds by reinjecting spent brine back into the aquifer, ensuring high water recovery and minimal net depletion.
The PFS establishes the project’s first JORC compliant reserves, derived from the mineral resource estimate completed on 30 October 2025:
Brine extraction is supported by a 36-well vertical wellfield designed to a depth of approximately 400m, with production wells spaced 400m apart. Locations were selected to remain within measured and indicated resource zones, to fall within the CEOL polygon (outside the lake exclusion zone) and to occupy CTL’s preferential licences. The reinjection strategy is specifically designed to maintain the basin’s hydraulic pressure, preventing the drawdown of shallow freshwater aquifers. Well selection was further supported by aquifer testing, notably at wells LV05 and LV06 where pumping tests demonstrated flow rates of up to 16L/s.
Well screens are set between 200m and 400m depth to target permeable volcanic units while limiting dilution from shallow freshwater or reinjected brine. The system is designed for a steady-state brine feed rate of ~568L/s by Year 2. Freshwater consumption at the salar site is estimated at 5.6L/s, whereas the Copiapó plant operates as a closed loop with 100% internal recirculation. Securing water rights and freshwater permitting remain critical path items for project development.
Electrical supply for the salar site is planned via a 130km transmission line under a build-own-operate-transfer (BOOT) model, targeting 100% renewable energy from Chile’s national grid. The project area is bisected by a paved international highway, facilitating reagent transport and export via Angamos Port. Water management focuses on internal recovery via reverse osmosis and mechanical vapour recompression. CTL has established a formal partnership with local indigenous communities to co-design the project’s environmental impact assessment, ensuring traditional ecological knowledge is integrated into the technical design ahead of a targeted 2026–2027 submission window.
The Laguna Verde PFS outlines compelling economics that place the project in the lowest
cost quartile of the global lithium industry. Based on a long-term lithium carbonate
price of
As of June 2025, CTL had £143k in cash (£2.1m net debt, plus c £15m in deferred licence payments), subsequently supplemented by a £5.0m gross equity placement in August to fund the acquisition of 30 additional licence blocks (7,500 hectares) essential for the CEOL polygon and to finalise the PFS. A recent VAT recovery in Chile of c £1.0m further supports near-term liquidity, alongside any potential small-scale equity placements and the upcoming ASX dual-listing. These funds should enable the company to further progress project permitting and technical studies.
With the PFS complete, the formal strategic partner selection process aims to attract investment from battery manufacturers or OEMs to fund longer-term project development through to the final investment decision. Additional important catalysts include final CEOL ratification (expected Q226), the ASX dual-listing and the initiation of the BFS. In our view, given the current share price disconnect from positive newsflow and strengthening lithium prices, CTL represents an attractive investment proposition for investors seeking exposure to a gradually de-risked, sustainable lithium developer.
General disclaimer and copyright
This report has been prepared and issued by Edison. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2026 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
Recce continues to advance its Phase III Indonesian-focused study of the topical gel formulation (R327G) of its lead anti-infective therapeutic drug candidate, RECCE 327 (R327), for the treatment of diabetic foot infections (DFIs). The company is on track to launch the drug in Indonesia by end-CY26 (and other ASEAN territories in CY27), pending positive interim results from the study (expected H2 CY26). This would mark Recce’s potential transition into a commercial-stage pharma company with recurring revenue to help fund pipeline expansion. The company also strengthened R327G’s potential breadth through its recently expanded preclinical-stage partnerships with the US Department of War for burn wound applications, and its development of an inhaled nebulised R327 formulation for the treatment of drug-resistant hospital or ventilator-associated pneumonia (HAP/VAP). We value Recce at A$611.2m (or A$2.28 per share).